What is the recommended titration protocol for increasing clozapine from a current dose of 350 mg daily, including dosing increments and required laboratory monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clozapine Titration from 350mg Upward

When increasing clozapine from 350 mg daily, titrate in increments of 100 mg or less, once or twice weekly, with a maximum daily dose of 900 mg, while maintaining divided dosing throughout the day. 1

Dosing Protocol

The FDA-approved titration strategy for doses above 300-450 mg is clear and conservative:

  • Increment size: 100 mg or less per adjustment
  • Frequency: Once or twice weekly (meaning every 7-14 days between increases)
  • Maximum dose: 900 mg daily
  • Dosing schedule: Continue divided doses throughout the day (not once daily) 1

This slower titration above 350 mg is critical because seizure risk is dose-dependent, and the gradual approach with divided dosing minimizes risks of orthostatic hypotension, bradycardia, and syncope 1.

Required Laboratory Monitoring

Since your patient is already on clozapine at 350 mg, they are past the initial 18-week period. The monitoring requirements are:

Blood Monitoring

  • ANC monitoring: Every 4 weeks (monthly) until 2 years post-commencement 2
  • Annual CBC: Full and complete blood count for haematological malignancies for the duration of therapy 2

Clozapine Level Monitoring

Check clozapine levels in these situations during dose escalation:

  • With any change in mental state
  • With change in adverse drug reactions (myoclonus, increased sedation, concomitant infection)
  • When CYP1A2 inhibiting co-medication is added or ceased
  • With infection/inflammatory illness 2

Target therapeutic range: 350-600 ng/mL (though some sources suggest 400 ng/mL as the threshold) 3

Adverse Drug Reaction Screening

Monitor at each ANC appointment for:

  • Metabolic syndrome parameters
  • Constipation and gastrointestinal hypomotility (critical safety issue)
  • Orthostatic hypotension and tachycardia
  • Seizures and myoclonus
  • Sedation
  • Other ADRs per the comprehensive checklist 2

Cardiac Monitoring

  • ECG: Consider annually (not mandatory but recommended by 63% consensus) 2
  • Echocardiogram: Only if clinically indicated, not routinely 2

Practical Titration Example from 350mg

Starting from 350 mg daily in divided doses:

  1. Week 1-2: Increase to 400-450 mg daily (50-100 mg increment)
  2. Week 3-4: If tolerated, increase to 500-550 mg daily
  3. Week 5-6: If needed, increase to 600-650 mg daily
  4. Continue this pattern until therapeutic response or maximum 900 mg daily

Critical Safety Considerations

Divided dosing is non-negotiable: The FDA label explicitly states "use divided dosage schedule" to minimize dose-related risks 1. Research shows once-daily dosing results in significantly lower plasma concentrations and only 8% of patients reaching therapeutic window versus 28% with divided dosing 4.

Watch for inflammation: Baseline and weekly CRP monitoring for at least 4 weeks after any significant dose increase can identify inflammation secondary to rapid titration 5. This is particularly important in Asian ancestry patients who may have lower CYP1A2 activity.

Drug interactions matter: If the patient is on CYP1A2 inhibitors (oral contraceptives, fluvoxamine, ciprofloxacin) or CYP3A4 inhibitors, you may need to reduce the dose increase increments or extend the time between increases 1.

Constipation surveillance: At every visit, actively screen for constipation as severe gastrointestinal hypomotility can be fatal with clozapine 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.